GoingToMeet

In the current economic climate, with governments under pressure to cut the cost of their national healthcare, and with governments then putting pressure on the pharmaceutical industry to lower prices, there has never been a greater need for companies in the industry to develop a truly innovative marketing strategy. Part of that strategy involves developing and maintaining partnerships with key opinion leaders. The challenge, however, is to do this in a pioneering fashion such that the relationship is transparent, fluent, mutually beneficial and at the end of the day, highly profitable. The traditional definition of a KOL is widening from just prescribers to include healthcare policy makers, regulators and other stakeholders. Learn how to recruit, manage, direct and develop a key opinion leader programme at SMi’s 3rd annual KOL: Key Opinion Leader Partnerships conference this September in London, UK. Learn from and debate with key players in this arena in our four discussion sessions:

》 Weighing the options in choosing your KOL 》 Should industry use KOLs without a direct involvement in the product development? 》 Employing KOLs through agencies – the arms length approach 》 Practical tips for working on common KOL projects

》 Partnership development 》 Payments strategies 》 KOL involvement in pricing and reimbursement issues 》 Managing KOLs in emerging markets 》 National and international KOL projects 》 Regulation of KOL-industry relationships